Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 12 h ago

Monte Rosa Therapeutics, Inc.: BIOTECHNOLOGY VALUE FUND L P amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Biotechnology Value Fund L.P. amended its Schedule 13G filing on Monte Rosa Therapeutics, Inc., disclosing its stake to the SEC under accession number 0000921895-26-003182. The filing is a passive-investor ownership update rather than a change in control, and the amended document did not disclose a revised share count or percentage in the headline data. The update matters because 13G amendments signal shifts in institutional ownership that can influence sentiment and liquidity in small-cap biotech names like Monte Rosa. Investors should watch for the specific share total and any change in the fund's passive status, and compare the revised position against prior filings to gauge whether the fund is accumulating or trimming.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Monte Rosa Therapeutics, Inc., BIOTECHNOLOGY VALUE FUND L P